Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model

Guoying Wang, Nanna Fyhrquist-Vanni, Henrik Wolff, Marie Caroline Dieu-Nosjean, L. Kemény, Bernard Homey, Antti I. Lauerma, Harri Alenius

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, for which no fundamental therapy exists. Immunostimulatory sequence CpG (ISS CpG) has potential in reducing susceptibility to allergic diseases and reversing established allergic reactions. Objective: To investigate the effects of ISS CpG in the prevention and treatment of AD in an AD murine model. Methods: BALB/c mice were epicutaneously exposed to ovalbumin (OVA) for 3 or 4 weeks with a 2-week resting period between each exposure week. ISS i.d. injection was given either on the 1st day of each exposure week (in the prevention experiment) or 3 days before and on the 1st, 4th and 7th day of the last exposure week (in the treatment experiment). Skin biopsy and blood were obtained at the end of the experiments. Results: ISS CpG treatment increased drastically mRNA expression of proinflammatory and Th1-type cytokines and chemokines in OVA-treated skin both in the prevention and treatment experiments. The suppressing effect of ISS CpG on Th2-type cytokines and chemokines was weak and limited to IL-13 and CCL24 in the treatment experiment. No significant reduction in OVA-elicited infiltration of eosinophils and T cells in the skin was seen after ISS administration but infiltration of plasmacytoid dendritic cells was absent in ISS CpG-treated skin. In contrast, ISS injection elicited dramatic infiltration of F4/80+ and CCR5+ cells into the dermis and subcutaneous tissue. Conclusion: Due to unwanted side effects and minor beneficial effects in our model, administration of ISS CpG may not be suitable for the treatment of AD in humans.

Original languageEnglish
Pages (from-to)41-51
Number of pages11
JournalInternational Archives of Allergy and Immunology
Volume147
Issue number1
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Atopic Dermatitis
Skin
Ovalbumin
Chemokines
Therapeutics
Cytokines
Injections
Interleukin-13
Subcutaneous Tissue
Dermis
Skin Diseases
Eosinophils
Dendritic Cells
Hypersensitivity
T-Lymphocytes
Biopsy
Messenger RNA

Keywords

  • Animal model
  • Atopic dermatitis
  • Chemokines
  • Cytokines
  • Immunostimulatory sequence CpG

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model. / Wang, Guoying; Fyhrquist-Vanni, Nanna; Wolff, Henrik; Dieu-Nosjean, Marie Caroline; Kemény, L.; Homey, Bernard; Lauerma, Antti I.; Alenius, Harri.

In: International Archives of Allergy and Immunology, Vol. 147, No. 1, 08.2008, p. 41-51.

Research output: Contribution to journalArticle

Wang, Guoying ; Fyhrquist-Vanni, Nanna ; Wolff, Henrik ; Dieu-Nosjean, Marie Caroline ; Kemény, L. ; Homey, Bernard ; Lauerma, Antti I. ; Alenius, Harri. / Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model. In: International Archives of Allergy and Immunology. 2008 ; Vol. 147, No. 1. pp. 41-51.
@article{ae6de3e599a04c39884baa270033856d,
title = "Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model",
abstract = "Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, for which no fundamental therapy exists. Immunostimulatory sequence CpG (ISS CpG) has potential in reducing susceptibility to allergic diseases and reversing established allergic reactions. Objective: To investigate the effects of ISS CpG in the prevention and treatment of AD in an AD murine model. Methods: BALB/c mice were epicutaneously exposed to ovalbumin (OVA) for 3 or 4 weeks with a 2-week resting period between each exposure week. ISS i.d. injection was given either on the 1st day of each exposure week (in the prevention experiment) or 3 days before and on the 1st, 4th and 7th day of the last exposure week (in the treatment experiment). Skin biopsy and blood were obtained at the end of the experiments. Results: ISS CpG treatment increased drastically mRNA expression of proinflammatory and Th1-type cytokines and chemokines in OVA-treated skin both in the prevention and treatment experiments. The suppressing effect of ISS CpG on Th2-type cytokines and chemokines was weak and limited to IL-13 and CCL24 in the treatment experiment. No significant reduction in OVA-elicited infiltration of eosinophils and T cells in the skin was seen after ISS administration but infiltration of plasmacytoid dendritic cells was absent in ISS CpG-treated skin. In contrast, ISS injection elicited dramatic infiltration of F4/80+ and CCR5+ cells into the dermis and subcutaneous tissue. Conclusion: Due to unwanted side effects and minor beneficial effects in our model, administration of ISS CpG may not be suitable for the treatment of AD in humans.",
keywords = "Animal model, Atopic dermatitis, Chemokines, Cytokines, Immunostimulatory sequence CpG",
author = "Guoying Wang and Nanna Fyhrquist-Vanni and Henrik Wolff and Dieu-Nosjean, {Marie Caroline} and L. Kem{\'e}ny and Bernard Homey and Lauerma, {Antti I.} and Harri Alenius",
year = "2008",
month = "8",
doi = "10.1159/000128585",
language = "English",
volume = "147",
pages = "41--51",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model

AU - Wang, Guoying

AU - Fyhrquist-Vanni, Nanna

AU - Wolff, Henrik

AU - Dieu-Nosjean, Marie Caroline

AU - Kemény, L.

AU - Homey, Bernard

AU - Lauerma, Antti I.

AU - Alenius, Harri

PY - 2008/8

Y1 - 2008/8

N2 - Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, for which no fundamental therapy exists. Immunostimulatory sequence CpG (ISS CpG) has potential in reducing susceptibility to allergic diseases and reversing established allergic reactions. Objective: To investigate the effects of ISS CpG in the prevention and treatment of AD in an AD murine model. Methods: BALB/c mice were epicutaneously exposed to ovalbumin (OVA) for 3 or 4 weeks with a 2-week resting period between each exposure week. ISS i.d. injection was given either on the 1st day of each exposure week (in the prevention experiment) or 3 days before and on the 1st, 4th and 7th day of the last exposure week (in the treatment experiment). Skin biopsy and blood were obtained at the end of the experiments. Results: ISS CpG treatment increased drastically mRNA expression of proinflammatory and Th1-type cytokines and chemokines in OVA-treated skin both in the prevention and treatment experiments. The suppressing effect of ISS CpG on Th2-type cytokines and chemokines was weak and limited to IL-13 and CCL24 in the treatment experiment. No significant reduction in OVA-elicited infiltration of eosinophils and T cells in the skin was seen after ISS administration but infiltration of plasmacytoid dendritic cells was absent in ISS CpG-treated skin. In contrast, ISS injection elicited dramatic infiltration of F4/80+ and CCR5+ cells into the dermis and subcutaneous tissue. Conclusion: Due to unwanted side effects and minor beneficial effects in our model, administration of ISS CpG may not be suitable for the treatment of AD in humans.

AB - Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, for which no fundamental therapy exists. Immunostimulatory sequence CpG (ISS CpG) has potential in reducing susceptibility to allergic diseases and reversing established allergic reactions. Objective: To investigate the effects of ISS CpG in the prevention and treatment of AD in an AD murine model. Methods: BALB/c mice were epicutaneously exposed to ovalbumin (OVA) for 3 or 4 weeks with a 2-week resting period between each exposure week. ISS i.d. injection was given either on the 1st day of each exposure week (in the prevention experiment) or 3 days before and on the 1st, 4th and 7th day of the last exposure week (in the treatment experiment). Skin biopsy and blood were obtained at the end of the experiments. Results: ISS CpG treatment increased drastically mRNA expression of proinflammatory and Th1-type cytokines and chemokines in OVA-treated skin both in the prevention and treatment experiments. The suppressing effect of ISS CpG on Th2-type cytokines and chemokines was weak and limited to IL-13 and CCL24 in the treatment experiment. No significant reduction in OVA-elicited infiltration of eosinophils and T cells in the skin was seen after ISS administration but infiltration of plasmacytoid dendritic cells was absent in ISS CpG-treated skin. In contrast, ISS injection elicited dramatic infiltration of F4/80+ and CCR5+ cells into the dermis and subcutaneous tissue. Conclusion: Due to unwanted side effects and minor beneficial effects in our model, administration of ISS CpG may not be suitable for the treatment of AD in humans.

KW - Animal model

KW - Atopic dermatitis

KW - Chemokines

KW - Cytokines

KW - Immunostimulatory sequence CpG

UR - http://www.scopus.com/inward/record.url?scp=49749085134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749085134&partnerID=8YFLogxK

U2 - 10.1159/000128585

DO - 10.1159/000128585

M3 - Article

VL - 147

SP - 41

EP - 51

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 1

ER -